Opportunity Information: Apply for RFA DA 25 073
This funding opportunity, RFA-DA-25-073, is a National Institutes of Health (NIH) discretionary grant that uses the R01 mechanism and is specifically designated as "Clinical Trial Not Allowed." The program supports exploratory research focused on uncovering biological and mechanistic links between substance use disorders (SUDs) and key aspects of HIV disease. The central emphasis is on studies that investigate how substance use and SUD-related factors influence HIV infection, viral replication, viral persistence and latency, and HIV-related pathogenesis. The scope also explicitly includes work on HIV-associated neurocognitive disorders (HAND), recognizing that neurological and cognitive outcomes are an important dimension of HIV disease biology, particularly in populations affected by substance use.
The scientific aim is broadly framed around mechanistic questions rather than service delivery, implementation, or clinical intervention testing. In practice, this means the opportunity is looking for research that can explain underlying pathways and processes, such as how specific substances or patterns of use may alter immune function, viral dynamics, tissue reservoirs, neuroinflammation, blood-brain barrier integrity, or other biological systems that shape HIV outcomes. Because the R01 clinical trial option is not allowed here, applicants should plan projects that do not involve assigning human participants to interventions to evaluate health-related outcomes in a way that meets NIH's definition of a clinical trial. Instead, the opportunity is geared toward foundational and translational mechanistic work that can include observational human studies, laboratory-based investigations, animal models, or other approaches appropriate for answering causal or mechanistic questions, as long as they do not cross into prohibited clinical trial territory.
Eligibility is intentionally broad and includes a wide range of domestic and international organizations. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); public housing authorities/Indian housing authorities; and Native American tribal organizations that are not federally recognized tribal governments. The opportunity is also open to nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education where relevant), for-profit organizations other than small businesses, and small businesses. In addition, the announcement highlights expanded eligibility for organizations such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; and non-domestic (non-U.S.) entities, meaning foreign organizations are explicitly included among potential applicants.
Key administrative details indicate this is a grant opportunity in the Education and Health activity category with CFDA number 93.279. The award ceiling is listed as $700,000, which signals the upper bound of funding expected per award under the terms of the opportunity. The announcement was created on 2024-09-09, and the original closing date for applications is 2025-08-14. While the expected number of awards is not specified in the provided source data, applicants should interpret the ceiling and the R01 format as pointing toward substantial, multi-aim research projects, provided they remain within the non-clinical-trial constraints and maintain a strong mechanistic focus.
Overall, the opportunity is designed for investigators who want to explain how substance use disorders intersect with HIV biology in ways that could ultimately inform prevention, treatment, and cure-related strategies, including efforts aimed at understanding and disrupting latency and persistent reservoirs. Competitive applications will likely be those that clearly define a mechanistic problem at the HIV-SUD interface, justify why the chosen models and methods can answer that mechanistic question, and articulate how the findings could meaningfully advance the field beyond descriptive associations.Apply for RFA DA 25 073
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2024-09-09.
- Applicants must submit their applications by 2025-08-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $700,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity number and sponsor?
The opportunity is RFA-DA-25-073 and it is sponsored by the National Institutes of Health (NIH).
What type of grant mechanism is used?
This opportunity uses the NIH R01 grant mechanism, which is generally intended for substantial, multi-aim research projects.
Are clinical trials allowed under this RFA?
No. The opportunity is explicitly designated as "Clinical Trial Not Allowed." Projects should be planned so they do not meet NIH's definition of a clinical trial (for example, assigning human participants to interventions to evaluate health-related outcomes).
What is the main scientific focus of this program?
The program supports exploratory research aimed at uncovering biological and mechanistic links between substance use disorders (SUDs) and key aspects of HIV disease biology.
What kinds of research questions are encouraged?
The emphasis is on mechanistic questions, such as how substance use or SUD-related factors influence HIV infection, viral replication, viral persistence and latency, and HIV-related pathogenesis.
Does the scope include neurological or cognitive outcomes in HIV?
Yes. The scope explicitly includes HIV-associated neurocognitive disorders (HAND), recognizing neurological and cognitive outcomes as an important dimension of HIV disease biology, particularly in populations affected by substance use.
What does "mechanistic" mean in the context of this opportunity?
In this context, "mechanistic" research aims to explain underlying biological pathways and processes (the "how" and "why"), rather than focusing on service delivery, implementation, or testing clinical interventions.
What types of study approaches are consistent with the "Clinical Trial Not Allowed" designation?
Approaches that may fit include observational human studies, laboratory-based investigations, animal models, and other methods appropriate for answering causal or mechanistic questions, as long as they do not cross into prohibited clinical trial territory.
What are examples of biological systems or processes mentioned as relevant?
The opportunity highlights areas such as immune function, viral dynamics, tissue reservoirs, neuroinflammation, and blood-brain barrier integrity, among other biological systems that shape HIV outcomes.
Is this opportunity focused on implementation, service delivery, or clinical intervention testing?
No. The scientific aim is framed around mechanistic biology rather than implementation research, service delivery programs, or clinical intervention testing.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic and international organizations, including governments, higher education institutions, nonprofit organizations, for-profit organizations (other than small businesses), and small businesses.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. Non-domestic (non-U.S.) entities are explicitly included among potential applicants.
What types of U.S. government entities are eligible?
Eligible applicants include state, county, city, or township governments; special district governments; and eligible federal agencies.
Are tribal entities eligible?
Yes. Eligible applicants include Native American tribal governments (federally recognized) and Native American tribal organizations that are not federally recognized tribal governments.
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education as well as private institutions of higher education.
Are minority-serving institutions specifically highlighted?
Yes. The announcement highlights expanded eligibility for organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are specifically highlighted among eligible organization types.
Are U.S. territories or possessions included?
Yes. U.S. territories or possessions are included among eligible applicants.
What is the activity category and CFDA number listed?
The opportunity is listed in the Education and Health activity category, with CFDA number 93.279.
What is the maximum (ceiling) award amount?
The award ceiling is listed as $700,000, indicating the upper bound of funding expected per award under the opportunity terms.
When was the announcement created?
The announcement was created on 2024-09-09.
What is the application closing date?
The original closing date for applications is 2025-08-14.
How many awards will be made?
The expected number of awards is not specified in the provided information.
What makes an application likely to be competitive for this RFA based on the description?
Applications are likely to be strongest when they clearly define a mechanistic problem at the HIV-SUD interface, justify why the proposed models and methods can answer that mechanistic question, and explain how the findings would advance the field beyond descriptive associations.
How does the opportunity connect to HIV persistence, latency, and cure-related research?
The description notes that the work can inform prevention, treatment, and cure-related strategies, including efforts aimed at understanding and disrupting HIV latency and persistent reservoirs, as long as the proposed work remains mechanistic and non-clinical-trial in nature.
Browse more opportunities from the same category: Education, Health
Next opportunity: FY25 IIJA/IRA Bureau of Land Management Oregon/Washington (ORWA) Cultural and Paleontological Resource Management
Previous opportunity: IIJA/IRA Bureau of Land Management National Operations Center (NOC) Invasive and Noxious Plant Management Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 25 073
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 25 073) also looked into and applied for these:
| Funding Opportunity |
|---|
| Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) Apply for PAR 24 297 Funding Number: PAR 24 297 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) Apply for PAR 24 298 Funding Number: PAR 24 298 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) Apply for PAR 24 299 Funding Number: PAR 24 299 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Health Equity through Interventions to Prevent and Address Housing Instability (R01 Clinical Trial Optional) Apply for RFA NR 25 001 Funding Number: RFA NR 25 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Apply for PAR 25 051 Funding Number: PAR 25 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed) Apply for RFA CA 24 036 Funding Number: RFA CA 24 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed) Apply for RFA DA 26 010 Funding Number: RFA DA 26 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed) Apply for RFA DA 26 009 Funding Number: RFA DA 26 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA CA 25 013 Funding Number: RFA CA 25 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) Apply for PA 25 080 Funding Number: PA 25 080 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required) Apply for RFA CA 25 010 Funding Number: RFA CA 25 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required) Apply for RFA CA 25 009 Funding Number: RFA CA 25 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required) Apply for RFA CA 24 031 Funding Number: RFA CA 24 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed) Apply for RFA CA 24 035 Funding Number: RFA CA 24 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: $850,000 |
| Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Center (U24 Clinical Trial Not Allowed) Apply for RFA CA 24 034 Funding Number: RFA CA 24 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $8,140,000 |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) Apply for PA 25 123 Funding Number: PA 25 123 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PA 25 121 Funding Number: PA 25 121 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required) Apply for RFA CA 24 030 Funding Number: RFA CA 24 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) Apply for PAR 24 304 Funding Number: PAR 24 304 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed) Apply for RFA CA 24 033 Funding Number: RFA CA 24 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,700,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 25 073", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.